-transparent.png){kind=logo}
Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (less than 3,500 cells/microl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.
Related Publications
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
April 1986,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
June 1984,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
February 1985,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
March 1986,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
September 1983,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
September 1983,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
September 1997,
Wiener klinische Wochenschrift,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
December 1987,
American journal of clinical oncology,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
May 1987,
Cancer treatment reports,
T P Miller, and
F R Ahmann, and
C Mackel, and
B R Greenberg, and
D S Alberts
March 1986,
Cancer treatment reports,
